Active Studies

This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded,
placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in
subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung
disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will
include about 314 patients at approximately 100 clinical trial centers. The treatment phase
of the study will last approximately 16 weeks. Patients who complete all required
assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3
study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to
determine the efficacy, safety and tolerability of APL-130277.

SELECT is a multicenter, observational prospective study implementing a protocol to acquire
imaging and clinical variables known to affect clinical outcomes after endovascular therapy
in an effort to evaluate and compare the different selection methods and criteria currently
used in practice for acute ischemic stroke patients in the anterior circulation with large
vessel occlusion. The study aim is to evaluate prospectively different selection
methodologies for endovascular therapy, to compare them against each other to identify which
method provides the highest predictive ability in the selection of patients for IAT and to
devise a formula that predicts patients' outcomes.

This study will enroll patients based on the recent AHA guidelines (July 2015) regarding
treatment of patients with acute ischemic strokes and large artery occlusions in the
anterior circulation.

12 month study testing mobile delivery of health information and connections to
professionals and peers to improve health of teen/young adult HPN users.

The purpose of the Alzheimer's Prevention Registry GeneMatch program is to identify a large
group of people interested in participating in research studies or clinical trials based in
part on their genetic background. This genetic information will be used to match interested
individuals to studies, providing a recruitment resource to the Alzheimer's scientific
community. Interested individuals should visit www.endALZnow.org/GeneMatch to join the
GeneMatch program.

Pages